Archive for September, 2016

EpiPen – the Reason for the Price Hike

http://articles.mercola.com/sites/articles/archive/2016/09/07/epipen-cost.aspx?utm_source=dnl&utm_medium=email&utm_content=art2&utm_campaign=20160907Z1&et_cid=DM118496&et_rid=1654866136

Those of you with allergies or who are using Bee Venom Therapy for MSIDS (multi systemic infectious disease syndrome – or Lyme with friends), have undoubtedly discovered the crazy price hike in Epi-pens.  

Although the epinephrine in the EpiPen costs about a dollar, the list price for a two-pack is currently over $600 in the U.S.  EpiPen sales brought in $1.2 billion in 2015 which meant a 461% price increase from 2007 to 2015.  Mylan CEO Heather Bresch got a 671% increase in  compensation and went from $2.5 million to $19 million.

“Mylan has tried to downplay the drug’s outrageous cost by saying that most patients have insurance coverage and they offer coupons to help reduce co-payments. People with high deductibles may still end up paying most of the costs out of pocket, however, and as The New York Times continued:4

Such co-payment assistance is part of the standard playbook for companies selling expensive drugs: The goal is to spare the consumer, who might create a political uproar, and yet still get paid by the insurance company or government health program.’

Ultimately, inflated drug costs are often passed down to consumers in the form of higher premiums from insurance companies and higher taxes to cover government health programs.

It should be noted, too, that most people have to purchase new EpiPens every year, even if they don’t use them, because they have a one-year expiration date. Some, however, are taking a gamble by keeping their expired EpiPens in lieu of spending hundreds of dollars on a new set.”

Mylan may be hiking prices before the introduction of a generic, which was expected last year, but U.S. Food and Drug Administration (FDA) rejected the generic version (made by Teva), and Sanofi’s Auvi-Q, another alternative, was pulled from the market due to problems with dosing.

The New York Times reported, “So rather than a last grasp for profits, Mylan has a near monopoly now, allowing it to continue the price increases for at least another year.”

Well I don’t know about your world, but where I live there are many MSIDS patients without insurance due to the fact insurance hardly ever covers proper treatment (anything outside the CDC guidelines of essentially 21 days of doxy), as well as the fact many are opposed to many unethical issues with Obamacare, as well as the fact they simply can’t afford it as they are paying out of pocket for proper MSIDS treatment outside the CDC’s box of horrors.  So the very people needing EpiPens are caught in the cross-fire and are without this insurance that’s supposed to pay these horrific prices.

Also, a bit of a history lesson on medical insurance from my 97 year old retired doctor who remembers:  Medical insurance was created to fill the gap from when farmers needed health care to when their crops came in, went to market, and they ultimately got paid so they could pay their own medical bill.  That’s it.  It helped them in the gap.

Ponder that and you will realize we have NOT “come a long way, baby.”  

Will the Most Reliable Lyme Test Please Stand Up?

https://vitalplan.com/blog/just-how-reliable-are-lyme-disease-lab-tests?utm_campaign=AUG+2016+Restore%3A+Epic+Guide%2C+Lyme+Disease+Test+%28szExxF%29&utm_medium=email&_ke=YWNhc2htYW5AY2hhcnRlci5uZXQ%3D&utm_source=Master+Restore+List+%28Live+Segment%21%29

Dr. Rawls explains about lab testing in this lengthy but informative article that is an excerpt from his book in progress on Lyme Disease.  You can also listen to the information below in his webinar (1.5 hours).

 

 

Lyme Cryme Video – Powerful

Cryme Disease: The Lyme Cryme Against Humanity
TRUTH from the LYMErix whistleblower

https://youtu.be/f8DU1Z6R-ms  Published on Sep 2, 2016.  Powerful hour long video explaining how the CDC purposely rigged the case definition of Lyme so cases would be missed.

Stress is placed on the fact that spirochetes are fungal shedders not bacteria.  This is important in semantics because unless you are using the same linguistics you will never come to an agreement, and that’s right where we are:  NO AGREEMENT IN THE MEDICAL COMMUNITY.

CDC Report on Zika

http://www.nejm.org/doi/full/10.1056/NEJMsr1604338  This CDC report has been cited as proof that Zika causes birth defects. 

But this little 3 minute video says it all.  Thank you to Forrest Maready for simply showing the facts.

If you have a bit more time (30 min) watch Dr. Bergman really dig into the facts covering everything from the fact they’ve tweaked the head circumference perimeters causing it to appear as if there are more cases of microcephaly to the fact that toxic exposure and malnutrition are huge factors for getting microcephaly (small head).  Also, the Brazilian government admitted to a dramatic over reporting and when they re-examined 404 babies with microcephaly only 17 tested positive for Zika. One third of cases were in the state Pernambuco were malnutrition and toxic exposure are rampant.

For more information: https://madisonarealymesupportgroup.com/2016/03/08/fixation-on-zikapolio/

https://madisonarealymesupportgroup.com/2016/04/08/zika-ebola-zombies-and-the-cdc/

https://madisonarealymesupportgroup.com/2016/07/17/zika-in-the-land-of-oz/

http://www.thevaccinereaction.org/2016/08/controversial-pesticide-naled-sprayed-over-miami-to-combat-zika/

“Naled is the same pesticide that, in June, the U.S. Centers for Disease Control and Prevention (CDC) recommended spraying in Puerto Rico to fight the spread of Zika virus infections there.4 5 However, following public protests by Puerto Ricans against the proposed pesticide spraying campaign, a lawsuit was filed on July 21 against the CDC and its director, Tom Frieden, in San Juan, Puerto Rico by that city’s Mayor Carmen Yulin Cruz-Soto and the San Juan Municipality. That lawsuit and opposition to the spraying by Puerto Rico’s Governor Alejandro Garcia Padilla prompted the CDC to back down on the use of Naled on the island.5 6 7″

How Lyme Spreads

http://www.cell.com/cell-reports/fulltext/S2211-1247(16)31059-2

Recently in Cell Reports researchers published information providing insight into how borrelia travels inside the human body allowing persistence.

Senior study author, Tara Moriarty, of the University of Toronoto states,

“Our in vitro live-cell-imaging system will permit more efficient dissection of the underlying interaction mechanisms and more rapid screening for inhibitors of bacterial-endothelial interactions and dissemination.”

They discovered that a cell-surface adhesion protein called BBK32 plays a role in stabilizing and strengthening bacterial-vascular interactions under blood flow and that the microbes use bungee-cord like tethers.

Similarly to children swinging on monkey bars, borrelia transfer force from one bond to the next without fully detaching, allowing them to move over endothelial surfaces at a constant speed much like leukocytes move through blood vessels.

Based on calculations utilizing the imaging system, researchers also believe that borrelia possibly use flagella to actively migrate along blood vessel walls, exiting the vasculature to reach specific sites against blood flow, much like swimmers in a river using their legs to kick toward trees lining the riverbank, then grabbing the tree branches to slow down, and finally pulling themselves up to exit the water to reach the shore.

First author, Thodaba Ebady of the University of Toronto, believes this ability is what gets borrelia to move through the body to evade the immune system causing persistence.

This finding points to creating drugs targeting BBK32 or other possible endothelial receptors to slow the spread of infection. It also points to the possible repurposing of current leukocyte-vascular inhibiting drugs used for autoimmune and inflammatory diseases to Lyme.

For the future, researchers want to identify the receptors BBK32 interacts with as well as determine the role of flagella in disease propagation as well as how the bacteria target specific endothelia. The researchers state they hope other labs utilize the approaches they’ve taken and they are happy to help them do so.